Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth
Citations Over Time
Abstract
Vemurafenib is a B-raf inhibitor which is widely used in treatment of melanoma patients with B-RAF V600E mutation. Majority of patients treated with vemurafenib develop resistance against the drug. Here, we asssessed the effectiveness of a combination drug therapy in vemurafenib resistant melanoma cells. Vemurafenib resistant A375 melanoma cells (A375Res cells) were developed by growing parental cells in increasing concentrations of the drug. The A375Res cells were 50 times more resistant (higher IC50 value), had reduced cell doubling time, were less responsive to the antiproliferative activity of Vemurafenib and showed increased tumor forming potential as compared to the parental cells. Vemurafenib inhibited phosphorylation of MEK 1/2 and ERK 1/2 at the concentrations far less than those that were effective in parental cells. Compared to the other drugs sorafenib in combination with vemurafenib significantly inhibited proliferation of A375Res cells. These findings show that Sorafenib, in combination with Vemurafenib, is a more effective method for treatment of melanoma with B-Raf 600E mutation.
Related Papers
- → RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)(2011)1,432 cited
- → Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma(2017)36 cited
- → Sorafenib regulating ERK signals pathway in gastric cancer cell(2014)2 cited
- → Abstract LB-428: RAS-independent dimerization of BRAF(V600E) splicing variants promotes resistance to RAF inhibitors(2012)
- → 809 Pou4f1 promotes braf inhibitor resistance by reactivating mapk signaling pathway in melanoma(2019)